Clinical Trial Update: Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and activity of 90Y-labeled IDEC-159 in patients with metastatic colorectal cancer; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• IDEC-159 (IDEC-159)

Snippet

Sponsor: Biogen | Conditions: Colorectal Cancer, Metastases | Phase 1, Phase 2 | Status: TERMINATED